Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications
Samo za registrovane korisnike
2011
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Objective: In vitro, stimulation of monocytes with antiphospholipid (aPL) antibodies resulted in increased secretion of TNF-alpha, but association of aPL with features of diabetes mellitus is not clarified yet. Therefore, we investigated the distribution of anticardiolipin (aCL), anti-beta 2gpI (a beta 2gpI), anti-annexin A5 (aannxA5), and anti-oxLDL (aoxLDL) antibodies, and TNF-alpha in well-formed group of 78 patients with type II diabetes mellitus without vascular complications. Methods: Investigated antibodies and TNF-alpha concentrations were measured by ELISA. Results: Antiphospholipid antibodies were in positive correlation with TNF-alpha concentrations: aCL IgG (r = 0.303, p = 0.007), aCL IgM (r = 0.386, p = 0.000), a beta 2gpI IgG (r = 0.499, p = 0.000), a beta 2gpI IgM (r = 0.462, p = 0.000), aanxA5 IgG (r = 0.479, p = 0.000), aanxA5 IgM (r = 0.641, p = 0.000), aoxLDL (IgG + IgM, r = 0.279, p = 0.000). Anticardiolipin-positive and aCL-negative subgroups differed in TNF-alpha ...concentrations (Mann-Whitney, p = 0.032). Significantly elevated LDL concentrations were noticed in aCL-positive patients with disease duration 10-15 years (chi(2) = 15.000, p = 0.000) and apoB concentrations were elevated in aoxLDL-positive patients with disease duration 7-10 years (chi(2) = 3.938, p = 0.047). Conclusion: Significant association of antiphospholipid antibodies and TNF-alpha might be a marker of severe atherogenic profile (suggested by increased levels of lipids in aPL-positive subgroups) and should be used for the stratification of patients with an increased risk for future deterioration of the disease.
Ključne reči:
Antiphospholipid antibodies / TNF-alpha / Diabetes mellitus type II / AtherosclerosisIzvor:
Cytokine, 2011, 55, 2, 301-306Izdavač:
- Academic Press Ltd- Elsevier Science Ltd, London
Finansiranje / projekti:
- Biomarkeri oštećenja i disfunkcije organa (RS-175036)
DOI: 10.1016/j.cyto.2011.05.001
ISSN: 1043-4666
PubMed: 21621418
WoS: 000293158100021
Scopus: 2-s2.0-80955179024
Institucija/grupa
PharmacyTY - JOUR AU - Becarević, Mirjana AU - Seferović, Jelena AU - Ignjatović, Svetlana AU - Singh, Sandra AU - Majkić-Singh, Nada PY - 2011 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1552 AB - Objective: In vitro, stimulation of monocytes with antiphospholipid (aPL) antibodies resulted in increased secretion of TNF-alpha, but association of aPL with features of diabetes mellitus is not clarified yet. Therefore, we investigated the distribution of anticardiolipin (aCL), anti-beta 2gpI (a beta 2gpI), anti-annexin A5 (aannxA5), and anti-oxLDL (aoxLDL) antibodies, and TNF-alpha in well-formed group of 78 patients with type II diabetes mellitus without vascular complications. Methods: Investigated antibodies and TNF-alpha concentrations were measured by ELISA. Results: Antiphospholipid antibodies were in positive correlation with TNF-alpha concentrations: aCL IgG (r = 0.303, p = 0.007), aCL IgM (r = 0.386, p = 0.000), a beta 2gpI IgG (r = 0.499, p = 0.000), a beta 2gpI IgM (r = 0.462, p = 0.000), aanxA5 IgG (r = 0.479, p = 0.000), aanxA5 IgM (r = 0.641, p = 0.000), aoxLDL (IgG + IgM, r = 0.279, p = 0.000). Anticardiolipin-positive and aCL-negative subgroups differed in TNF-alpha concentrations (Mann-Whitney, p = 0.032). Significantly elevated LDL concentrations were noticed in aCL-positive patients with disease duration 10-15 years (chi(2) = 15.000, p = 0.000) and apoB concentrations were elevated in aoxLDL-positive patients with disease duration 7-10 years (chi(2) = 3.938, p = 0.047). Conclusion: Significant association of antiphospholipid antibodies and TNF-alpha might be a marker of severe atherogenic profile (suggested by increased levels of lipids in aPL-positive subgroups) and should be used for the stratification of patients with an increased risk for future deterioration of the disease. PB - Academic Press Ltd- Elsevier Science Ltd, London T2 - Cytokine T1 - Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications VL - 55 IS - 2 SP - 301 EP - 306 DO - 10.1016/j.cyto.2011.05.001 ER -
@article{ author = "Becarević, Mirjana and Seferović, Jelena and Ignjatović, Svetlana and Singh, Sandra and Majkić-Singh, Nada", year = "2011", abstract = "Objective: In vitro, stimulation of monocytes with antiphospholipid (aPL) antibodies resulted in increased secretion of TNF-alpha, but association of aPL with features of diabetes mellitus is not clarified yet. Therefore, we investigated the distribution of anticardiolipin (aCL), anti-beta 2gpI (a beta 2gpI), anti-annexin A5 (aannxA5), and anti-oxLDL (aoxLDL) antibodies, and TNF-alpha in well-formed group of 78 patients with type II diabetes mellitus without vascular complications. Methods: Investigated antibodies and TNF-alpha concentrations were measured by ELISA. Results: Antiphospholipid antibodies were in positive correlation with TNF-alpha concentrations: aCL IgG (r = 0.303, p = 0.007), aCL IgM (r = 0.386, p = 0.000), a beta 2gpI IgG (r = 0.499, p = 0.000), a beta 2gpI IgM (r = 0.462, p = 0.000), aanxA5 IgG (r = 0.479, p = 0.000), aanxA5 IgM (r = 0.641, p = 0.000), aoxLDL (IgG + IgM, r = 0.279, p = 0.000). Anticardiolipin-positive and aCL-negative subgroups differed in TNF-alpha concentrations (Mann-Whitney, p = 0.032). Significantly elevated LDL concentrations were noticed in aCL-positive patients with disease duration 10-15 years (chi(2) = 15.000, p = 0.000) and apoB concentrations were elevated in aoxLDL-positive patients with disease duration 7-10 years (chi(2) = 3.938, p = 0.047). Conclusion: Significant association of antiphospholipid antibodies and TNF-alpha might be a marker of severe atherogenic profile (suggested by increased levels of lipids in aPL-positive subgroups) and should be used for the stratification of patients with an increased risk for future deterioration of the disease.", publisher = "Academic Press Ltd- Elsevier Science Ltd, London", journal = "Cytokine", title = "Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications", volume = "55", number = "2", pages = "301-306", doi = "10.1016/j.cyto.2011.05.001" }
Becarević, M., Seferović, J., Ignjatović, S., Singh, S.,& Majkić-Singh, N.. (2011). Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications. in Cytokine Academic Press Ltd- Elsevier Science Ltd, London., 55(2), 301-306. https://doi.org/10.1016/j.cyto.2011.05.001
Becarević M, Seferović J, Ignjatović S, Singh S, Majkić-Singh N. Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications. in Cytokine. 2011;55(2):301-306. doi:10.1016/j.cyto.2011.05.001 .
Becarević, Mirjana, Seferović, Jelena, Ignjatović, Svetlana, Singh, Sandra, Majkić-Singh, Nada, "Significant association of antiphospholipid antibodies and TNF-alpha: Marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications" in Cytokine, 55, no. 2 (2011):301-306, https://doi.org/10.1016/j.cyto.2011.05.001 . .